AMO Pharma Limited today announced that the first patient has completed participation in the REACH-CDM pivotal clinical trial and has been enrolled in the REACH-CDM X study
| LONDON, Sept. 30, 2021 /PRNewswire/ -- AMO Pharma Limited (“AMO Pharma”), a privately held biopharmaceutical company focusing on rare, childhood-onset neurogenetic disorders with limited or no treatment options, today announced that the first patient has completed participation in the REACH-CDM pivotal clinical trial and has been enrolled in the REACH-CDM X study, a 52-week open-label study designed to evaluate the long-term safety and efficacy of AMO-02 (tideglusib), AMO Pharma’s investigational therapy for the treatment of congenital myotonic dystrophy (DM1). “The enrollment of the first patient in the REACH-CDM X open-label extension study for AMO-02 highlights the progress we are making with the REACH-CDM pivotal trial,” said Joseph P. Horrigan, MD, AMO Pharma’s chief medical officer. “Following participation in the REACH-CDM pivotal trial, patients are eligible to transition into the open-label trial where they will be treated with study drug for 12 months. This study will provide important additional insights that will help us better assess the long-term safety and efficacy profile of AMO-02.” The REACH-CDM X open-label study will include assessments of the long-term safety of treatment with AMO-02 as well as a range of efficacy measures. The REACH-CDM pivotal trial is a double-blind, placebo-controlled, randomized study in children and adolescents with congenital-onset myotonic dystrophy intended to support a future submission for marketing authorization in congenital myotonic dystrophy. The trial is currently enrolling a total of 56 patients at sites in the U.S., Canada, and New Zealand, with additional sites in Australia and other countries to be added pending local approvals. Patients will be assessed on a range of measures of CNS features and muscle function associated with CDM1 using a primary outcome measure agreed to by the FDA. “We are very pleased to report this important milestone in our clinical program for DM1, which brings patients who have completed participation in our pivotal trial the opportunity to be treated with AMO-02 for 12 months,” said Dr. Michael Snape, chief science officer at AMO Pharma. “We are grateful to our outstanding team of investigators and to all the patients and families who have expressed interest in participating in this trial and we are working tirelessly to advance this program to the final stages of clinical development.” Additional information about the REACH-CDM trial is available at https://www.reachcdm.com/. About AMO-02 About AMO Pharma Media:
SOURCE AMO Pharma |
View original content:
